JNJ
Pharma

J&J's immunology portfolio compensates for Stelara's LOE

J&J's recent growth surge has come despite the LOE of Stelara. Compensating for the shortfall is Tremfya, which topped the $2 billion mark in Q2.
Kevin Dunleavy Jul 15, 2026 11:30am
9 of the Top 10 Pharma Manufacturers Partner with Redi Health to Lead the Next-Generation Patient Experience

9 of the Top 10 Pharma Manufacturers Choose Redi Health

Brought to you by Redi Health
hair hair loss baldness female pattern hair loss

Veradermics reports ph. 2 win in female pattern hair loss

Jul 15, 2026 11:27am
Clinical Success Is No Longer One Number

Clinical Success Is No Longer One Number

Brought to you by Intelligencia AI
Kelun

Kelun's sac-TMT win offers blueprint for Merck's global gap

Jul 15, 2026 10:20am
AI drug discovery AI artificial intelligence

Bora inks $2.5B deal with drug discovery AI specialist Insilico

Jul 15, 2026 7:08am
More News

Celcuity set to be Big Pharma 'strategic target' after approval

Jul 14, 2026 4:56pm

Huyabio's HDAC inhibitor scores in phase 3 melanoma study

Jul 14, 2026 10:48am

Regulatory tracker: Leqembi scores FDA nod for subQ starter dose

Jul 14, 2026 10:40am

Cellares' recent wins have opened the floodgates for the IDMO

Jul 14, 2026 10:26am